Hovione

Executive Summary

Hovione is a leading integrated Contract Development and Manufacturing Organization (CDMO) with over 60 years of experience, headquartered in Loures, Portugal, and a registered office in Ireland. The company specializes in complex small molecule drug substance and drug product manufacturing, with particular expertise in inhalation and solubility enhancement technologies. Its core philosophy, 'In it for life,' underscores a commitment to quality, integrity, and patient-centric service. Hovione's end-to-end capabilities span from early development to commercial production, serving both innovator and generic pharmaceutical companies. The company's long-standing track record, robust regulatory compliance, and investment in advanced manufacturing infrastructure position it as a trusted partner in the CDMO landscape. Looking ahead, Hovione is poised to benefit from increasing demand for complex generics and specialized drug delivery solutions. The company's focus on high-value, technically challenging products such as inhalables and poorly soluble drugs aligns with industry trends toward personalized medicine and the growing prevalence of chronic respiratory and metabolic diseases. While privately held and not publicly traded, Hovione's strategic investments in capacity expansion and process innovation are expected to drive revenue growth and market share gains. Key financial performance indicators remain undisclosed, but the company's sustained growth over decades suggests resilient operations and a strong competitive moat.

Upcoming Catalysts (preview)

• Q1 2027Completion of inhalation manufacturing facility expansion in Portugal80% success
• Q4 2026Launch of new lipid-based solubility enhancement platform for oral drugs70% success
• Q2 2027Signing of a long-term strategic partnership with a top 20 pharma for multiple programs60% success